MR parkinsonism index predicts vertical supranuclear gaze palsy in patients with PSP–parkinsonism. (20th September 2016)

• Record Type: Journal Article
• Authors: Quattrone, Aldo; Morelli, Maurizio; Williams, David R.; Vescio, Basilio; Arabia, Gennarina; Nigro, Salvatore; Nicoletti, Giuseppe; Salsone, Maria; Novellino, Fabiana; Nisticò, Rita; Pucci, Franco; Chiriaco, Carmelina; Pugliese, Pierfrancesco; Bosco, Domenico; Caracciolo, Manuela
• Is Part Of: Neurology. Volume 87:Number 12(2016)
• Publication Date: 2016-09-20
• Subjects: Neurology -- Periodicals; Neurology -- Periodicals; Neurologie -- Périodiques; 616.8
• DOI: 10.1212/WNL.0000000000003125
• Languages: English
• ISSNs: 0028-3878

Abstract

Abstract : Objective: To identify a biomarker for predicting the appearance of vertical supranuclear gaze palsy (VSGP) in patients affected by progressive supranuclear palsy–parkinsonism (PSP-P). Methods: Twenty-four patients with PSP-P were enrolled in the current study. Patients were clinically followed up every 6 months until the appearance of VSGP or the end of the follow-up (4 years). Participants underwent MRI at baseline and at the end of follow-up. Magnetic resonance parkinsonism index (MRPI), an imaging measure useful for diagnosing PSP, was calculated. Results: Twenty-one patients with PSP-P completed follow-up, and 3 patients dropped out. Eleven of 21 patients with PSP-P developed VSGP after a mean follow-up period of 28.5 months (range 6–48 months), while the remaining 10 patients with PSP-P did not develop VSGP during the 4-year follow-up period. At baseline, patients with PSP-P who later developed VSGP had MRPI values significantly higher than those of patients not developing VSGP without overlapping values between the 2 groups. MRPI showed a higher accuracy (100%) in predicting VSGP than vertical ocular slowness (accuracy 33.3%) or postural instability with or without vertical ocular slowness (accuracy 71.4% and 42.9%, respectively). Conclusions: Our study demonstrates that MRPI accurately predicted, on an individual basis, the appearance of VSGP in patients with PSP-P, thus confirming clinical diagnosis in vivo.